854813-77-7

Basic information

• Product Name: N-(4-aminophenyl)-3-(dimethylamino)propanamide
• Synonyms: N-(4-aminophenyl)-3-(dimethylamino)propanamide
• CAS NO: 854813-77-7
• Molecular Formula: C₁₁H₁₇N₃O
• Molecular Weight: 207.275
• Mol File: 854813-77-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-aminophenyl)-3-(dimethylamino)propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-aminophenyl)-3-(dimethylamino)propanamide(854813-77-7)
• EPA Substance Registry System: N-(4-aminophenyl)-3-(dimethylamino)propanamide(854813-77-7)

Safety Data

• Hazardous Substances Data: 854813-77-7(Hazardous Substances Data)

Upstream product

• 100-01-6 4-nitro-aniline 
• 19313-88-3 3-chloro-N-(4-nitrophenyl)propanamide 
• 854813-63-1 3-dimethylamino-N-(4-nitro-phenyl)-propionamide 

Downstream Products

• 921201-93-6 N-(4-azido-phenyl)-3-dimethylamino-propionamide 
• 1070978-54-9 1,3-bis(3-(4-(3-(dimethylamino)propanamido)phenylcarbamoyl)phenyl)urea 
• 1191091-12-9 N₄,N₅-bis(4-(3-(dimethylamino)propanamido)phenyl)-9,10-dihydro-9-oxoacridine-4,5-dicarboxamide 
• 1446421-20-0 N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)-phenyl)-3-(dimethylamino)propanamide 

Relevant articles and documents

Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach

A series of new, water-soluble phenyl N-mustard-benzenealkylamide conjugates containing hydrophilic ω-dialkylaminoalkylamide or ω-cyclic aminoalkylamide moieties were synthesized via a bioisostere approach. These compounds have a broad spectrum of antitumor activity against a panel of human tumor cell lines. Of these derivatives, compound 18b effectively suppressed the growth of colon cancer (HCT-116), prostate cancer (PC3), and lung cancer (H460) xenografts. The growth of HCT-116 xenografts was almost completely suppressed when co-treated with compound 18b and 5-fluorouracil. Furthermore, compound 18b can induce DNA cross-linking and cell-cycle arrest at the G2/M phase. Early preclinical studies, including pharmacokinetics in rats, inhibition of the hERG, and 14 days of acute intravenous injection toxicity, suggest that compound 18b is a promising candidate for further preclinical studies.

UREYLENE DERIVATIVES

The invention concerns compounds of Formula (I) or a salt, solvate or pro-drug thereof. The compounds may be used in therapy, particularly anti-cancer therapy.

Rational design of substituted diarylureas: A scaffold for binding to G-quadruplex motifs

The design and synthesis of a series of urea-based nonpolycyclic aromatic ligands with alkylaminoanilino side chains as telomeric and genomic G-quadruplex DNA interacting agents are described. Their interactions with quadruplexes have been examined by means of fluorescent resonance energy transfer melting, circular dichroism, and surface plasmon resonance-based assays. These validate the design concept for such urea-based ligands and also show that they have significant selectivity over duplex DNA, as well as for particular G-quadruplexes. The ligand-quadruplex complexes were investigated by computational molecular modeling, providing further information on structure-activity relationships. Preliminary biological studies using short-term cell growth inhibition assays show that some of the ligands have cancer cell selectivity, although they appear to have low potency for intracellular telomeric G-quadruplex structures, suggesting that their cellular targets may be other, possibly oncogene-related quadruplexes.